stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Return on equity
Exelixis, Inc.'s return on equity over the twelve months to 30 September 2026 was 44.3%, up 8.8 percentage points from fiscal 2025 (35.5%). Over the past ten years it has ranged from 6.27% (fiscal 2020) to 272.8% (fiscal 2016); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 35.5% | 12.40 |
| FY2024 | 23.1% | 14.39 |
| FY2023 | 8.74% | 0.98 |
| FY2022 | 7.76% | (3.54) |
| FY2021 | 11.3% | 5.03 |
| FY2020 | 6.27% | (15.32) |
| FY2019 | 21.6% | (66.18) |
| FY2018 | 87.8% | 5.36 |
| FY2017 | 82.4% | (190.36) |
| FY2016 | 272.8% | 146.23 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| HALO Halozyme Therapeutics, Inc. compare | 216.4% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 138.1% |
| ASND Ascendis Pharma A/S compare | 118.4% |
| EXEL Exelixis, Inc. | 44.3% |
| BBIO BridgeBio Pharma, Inc. compare | 26.2% |
| JAZZ Jazz Pharmaceuticals PLC compare | 5.05% |
| BNTX BioNTech SE Sponsored ADR compare | −8.29% |
| INSM Insmed, Inc. compare | −72.5% |
| SMMT Summit Therapeutics PLC compare | −192.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement